SCHEMBL24671812

SCHEMBL24671812

COC(=O)c1ccc2c(c1)cc(B(O)O)n2C(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.38
NR1H2 P55055 8/20 0.37
LCK P06239 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
CA12 O43570 2/20 0.36
CA9 Q16790 2/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36
XDH P47989 1/20 0.36
CA14 Q9ULX7 1/20 0.36
ALOX15 P16050 1/20 0.36
HTT P42858 1/20 0.36
PTPN11 Q06124 1/20 0.36
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
PTGS2 P35354 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30066574 1.00 KDM4E (0.38) KDM4ENR1H2LCKHDAC1HDAC6
SCHEMBL1622515 0.90 KDM4E (0.37) KDM4ENR1H2LCKHDAC1HDAC6
SCHEMBL12717579 0.88 NR1H2 (0.37) NR1H2CA12CA9GABRG2GABRB3
SCHEMBL30066464 0.87 CA12 (0.40) NR1H2CA12CA9CA1CA2
SCHEMBL23327918 0.84 AURKA (0.44) NR1H2CA12CA9
SCHEMBL12913197 0.82 LMNA (0.41) NR1H2
SCHEMBL29955030 0.82 NR1H2 (0.46) KDM4ENR1H2CA12CA9PTGS2
SCHEMBL22938845 0.82 PTGS2 (0.43) KDM4ENR1H2LCKHDAC1HDAC6
SCHEMBL1497620 0.82 NR1H2 (0.46) KDM4ENR1H2CA12CA9PTGS2
SCHEMBL17690271 0.82 ESR2 (0.40) NR1H2CA12CA9GABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117693502-A Compounds for inhibiting or degrading ITK, compositions comprising the same, methods of making the same, and methods of using the same 纽力克斯治疗公司 2024-03-12 CN disclosed
US-20230212144-A1 5-MEMBERED HETEROARYL DERIVATIVE CONTAINING AT LEAST ONE N, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDERS, CONTAINING SAME AS ACTIVE INGREDIENT TRINEURO (KR) 2023-07-06 US disclosed
WO-2022235715-A1 COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE NURIX THERAPEUTICS, INC. (US) 2022-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212144-A1 5-MEMBERED HETEROARYL DERIVATIVE CONTAINING AT LEAST ONE N, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDERS, CONTAINING SAME AS ACTIVE INGREDIENT HTR5A, HTR2C, TPH1 KDM4E 1651/4885NR1H2 1642/4885LCK 4278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.